Dora Hatzidaki

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

John Souglakos, Ioannis Boukovinas, Miquel Tarón et al. · British Journal of Cancer · 2008 · 117 citations · Full text

Tumor Biology, Oncogenic Agent, Medicine +14

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer

Anna Daskalaki, Sofia Agelaki, Maria Perraki et al. · British Journal of Cancer · 2009 · 99 citations · Full text

Frontline Treatment of Advanced Gastric Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor (G-CSF)

Dimitriοs Mavroudis, C. Kourousis, N. Androulakis et al. · American Journal of Clinical Oncology · 2000 · 95 citations

Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status

Aristea Kalikaki, Anastasios Koutsopoulos, Dora Hatzidaki et al. · Lung Cancer · 2009 · 88 citations

Medicine, Pathology, K-ras Mutation Status +7

First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: A multicenter phase II study

Vassilis Georgoulias, N. Androulakis, Meletios Α. Dimopoulos et al. · Annals of Oncology · 1998 · 71 citations

Medicine, Metronomic Therapy, Bronchial Neoplasm +8